+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-a4ß7 Integrin Monoclonal Antibody Market - Global Forecast 2026-2032- Product Image
Anti-a4ß7 Integrin Monoclonal Antibody Market - Global Forecast 2026-2032- Product Image
Sale

Anti-a4ß7 Integrin Monoclonal Antibody Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118069
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-α4β7 Integrin Monoclonal Antibody Market is projected to reach USD 3.43 Billion in 2026. It is expected to continue growing at a CAGR of 10.08%, reaching USD 6.12 Billion by 2032.

Anti-α4β7 Integrin Monoclonal Antibodies: Executive Overview

Anti-α4β7 integrin monoclonal antibodies are targeted biologic therapies designed to modulate lymphocyte trafficking by blocking interaction between α4β7 integrin and mucosal addressin cell adhesion molecule-1. Their most established clinical relevance is in immune-mediated gastrointestinal disease, where selective gut activity can support disease control while potentially limiting broader systemic immunosuppression. The market is shaped by clinical evidence, treatment guidelines, biomarker development, reimbursement, infusion infrastructure, and competition from other advanced therapies.

Clinical Selectivity and Treatment-Pathway Changes Are Reshaping Adoption

The landscape is moving toward earlier treatment optimization, objective disease monitoring, and more individualized sequencing of biologic and small-molecule therapies. Physicians increasingly assess endoscopic, imaging, laboratory, and patient-reported outcomes together rather than relying only on symptoms. Safety monitoring, route of administration, dosing convenience, persistence, and payer requirements are becoming as important as efficacy when therapies are positioned within established treatment pathways. Regulatory expectations also increasingly emphasize durable benefit, quality of life, and evidence across clinically relevant patient subgroups.

Artificial Intelligence Is Strengthening Discovery, Trial Design, and Patient Management

Artificial intelligence can influence this field through target validation, antibody engineering, biomarker discovery, trial feasibility assessment, and identification of patients most likely to respond. In clinical development, machine-learning tools may improve cohort selection, detect treatment-response patterns, and support decentralized data capture from imaging, laboratory results, and clinical records. In practice, decision-support systems could help identify loss of response and guide monitoring, although clinical validation, data quality, privacy, explainability, and regulatory oversight remain essential before broad deployment.

Regional Differences Reflect Regulatory Maturity, Access, and Specialist Capacity

North America is characterized by established biologic treatment pathways, specialist gastroenterology networks, and comparatively mature reimbursement mechanisms, while access remains influenced by prior authorization and care affordability. Europe combines strong clinical research capabilities with country-level variation in health-technology assessment, procurement, and reimbursement. Asia-Pacific presents a mixed environment: Australia, Japan, and South Korea have advanced regulatory and specialist infrastructures, while access and diagnostic capacity vary across other markets. Latin America is shaped by uneven biologic availability, public-private system differences, and reimbursement constraints. The Middle East shows concentrated specialist capacity and growing investment in advanced care, whereas Africa remains highly heterogeneous, with diagnosis, cold-chain logistics, and affordability as important determinants of access.

Economic Blocs Shape Evidence Requirements, Procurement, and Treatment Access

ASEAN markets differ substantially in regulatory processes, specialist availability, and biologic reimbursement, making localized access strategies important. BRICS economies combine large and diverse patient populations with differing domestic manufacturing capabilities, public procurement models, and affordability constraints. The European Union benefits from shared scientific and regulatory structures but retains national variation in health-technology assessment and payment decisions. G7 countries generally offer sophisticated clinical infrastructures and extensive evidence requirements, while budget impact and treatment sequencing remain central. GCC countries often have well-resourced tertiary centers but rely on coordinated procurement and specialist referral systems. NATO members span multiple health systems, so common defense and regulatory affiliations do not eliminate national differences in reimbursement or care delivery.

Country-Level Priorities Range from Innovation Access to Health-System Capacity

The United States and Canada combine specialist expertise with complex payer and authorization environments. In Europe, France, Germany, Italy, Spain, and the United Kingdom differ in assessment, procurement, prescribing, and regional implementation despite strong clinical capabilities. Japan and South Korea have advanced biologic infrastructures supported by detailed regulatory and reimbursement frameworks. Australia has established specialist care but faces geographic concentration of services. China and India are influenced by expanding biotechnology capacity, heterogeneous access, and major urban-rural differences. Brazil, Mexico, and Russia reflect varied public and private pathways, affordability considerations, and regional disparities in diagnosis and treatment continuity.

Leaders Should Prioritize Evidence Quality, Access Design, and Patient-Centered Delivery

Industry leaders should generate comparative, real-world evidence that clarifies positioning across treatment lines, disease severity, comorbidity profiles, and prior biologic exposure. They should pair clinical efficacy with durable remission, steroid-sparing outcomes, safety, quality of life, and healthcare-resource evidence. Access planning should address payer evidence requirements, infusion or administration capacity, cold-chain reliability, and patient support without creating inappropriate treatment incentives. Partnerships with clinicians and patient organizations can improve adherence and outcome measurement, while validated digital and artificial-intelligence tools should be introduced only with clear governance, bias controls, and clinical accountability.

Methodology Combines Verified Clinical, Regulatory, and Health-System Evidence

This executive summary uses a structured review of publicly available, authoritative evidence, including regulatory documents, clinical-trial records, peer-reviewed research, treatment guidelines, health-technology assessments, reimbursement policies, and government or intergovernmental health sources. Findings were organized across therapeutic mechanisms, clinical development, treatment pathways, regional systems, economic groups, and country-level access conditions. Qualitative conclusions were retained only where supported by documented evidence, and no market estimates, market shares, forecasts, or company-specific claims were used.

Selective Biologic Action Supports Continued Focus on Outcomes and Access

Anti-α4β7 integrin monoclonal antibodies occupy an important position in targeted immune-mediated disease care because they address a defined trafficking pathway with clinically relevant gut selectivity. Future progress will depend less on mechanism alone than on demonstrating durable patient benefit, integrating objective monitoring, improving treatment convenience, and navigating increasingly differentiated access environments. Evidence-led positioning, responsible use of artificial intelligence, and regionally adapted delivery models will be central to sustainable advancement.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Indication
7.1. Introduction
7.2. Crohn's Disease
7.2.1. Colonic
7.2.2. Ileal
7.2.3. Ileocolonic
7.3. Indeterminate Colitis
7.4. Microscopic Colitis
7.5. Ulcerative Colitis
7.5.1. Left-Sided Colitis
7.5.2. Pancolitis
7.5.3. Proctitis
8. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Administration Route
8.1. Introduction
8.2. Intravenous Infusion
8.3. Subcutaneous Injection
9. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Line Of Therapy
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line And Beyond
10. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Dosage Form
11.1. Introduction
11.2. Autoinjector
11.3. Prefilled Syringe
11.4. Single Dose Vial
12. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abcam
16.2. ACROBiosystems
16.3. Aladdin Scientific
16.4. Biorbyt
16.5. Bioss Inc.
16.6. BosterBio
16.7. Creative Diagnostics
16.8. GeneTex
16.9. ichorbio
16.10. Leinco Technologies
16.11. MyBioSource.com
16.12. Novus Biologicals
16.13. OriGene Technologies
16.14. R&D Systems
16.15. Santa Cruz Biotechnology, Inc.
16.16. Selleck Chemicals
16.17. Sino Biological
16.18. Thermo Fisher Scientific
16.19. United States Biological
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Anti-a4ß7 Integrin Monoclonal Antibody Market, Years Considered for the Study
FIGURE 2. Global Anti-a4ß7 Integrin Monoclonal Antibody Market, Research Design
FIGURE 3. Global Anti-a4ß7 Integrin Monoclonal Antibody Market, Research Framework
FIGURE 4. Global Anti-a4ß7 Integrin Monoclonal Antibody Market, Data Triangulation
FIGURE 5. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 9. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2025 vs 2032 (%)
FIGURE 11. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 15. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Segmentation & Coverage
TABLE 2. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 3. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Crohn's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Crohn's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Crohn's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Colonic Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Colonic Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Colonic Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Ileal Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Ileal Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Ileal Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Ileocolonic Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Ileocolonic Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Ileocolonic Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Indeterminate Colitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Indeterminate Colitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Indeterminate Colitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Microscopic Colitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Microscopic Colitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Microscopic Colitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Ulcerative Colitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Ulcerative Colitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Ulcerative Colitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Left-Sided Colitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Left-Sided Colitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Left-Sided Colitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Pancolitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Pancolitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Pancolitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Proctitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Proctitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Proctitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 35. Global Intravenous Infusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Intravenous Infusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Intravenous Infusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 42. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 52. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 62. Global Autoinjector Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Autoinjector Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Autoinjector Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Single Dose Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Single Dose Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Single Dose Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 80. North America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. North America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 82. North America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 83. North America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 84. North America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 85. North America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 86. North America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 87. North America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 88. Latin America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Latin America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 90. Latin America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 91. Latin America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 92. Latin America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 93. Latin America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 94. Latin America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 95. Latin America Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 96. Europe Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Europe Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 98. Europe Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 99. Europe Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 100. Europe Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 101. Europe Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 102. Europe Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 103. Europe Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 104. Middle East Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Middle East Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 106. Middle East Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 107. Middle East Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 108. Middle East Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 109. Middle East Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 110. Middle East Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 111. Middle East Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 112. Africa Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Africa Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 114. Africa Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 115. Africa Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 116. Africa Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 117. Africa Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 118. Africa Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 119. Africa Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 120. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. ASEAN Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. ASEAN Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 123. ASEAN Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 124. ASEAN Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 125. ASEAN Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 126. ASEAN Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 127. ASEAN Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 128. ASEAN Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 129. GCC Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. GCC Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 131. GCC Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 132. GCC Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 133. GCC Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 134. GCC Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 135. GCC Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 136. GCC Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 137. European Union Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. European Union Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 139. European Union Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 140. European Union Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 141. European Union Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 142. European Union Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 143. European Union Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 144. European Union Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 145. BRICS Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. BRICS Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 147. BRICS Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 148. BRICS Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 149. BRICS Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 150. BRICS Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 151. BRICS Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 152. BRICS Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 153. G7 Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. G7 Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 155. G7 Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 156. G7 Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 157. G7 Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 158. G7 Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 159. G7 Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 160. G7 Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 161. NATO Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. NATO Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 163. NATO Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 164. NATO Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 165. NATO Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 166. NATO Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 167. NATO Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 168. NATO Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 169. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. United States Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 171. United States Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 172. United States Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 173. United States Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 174. United States Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 175. United States Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 176. United States Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 177. United States Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 178. Canada Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 179. Canada Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 180. Canada Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 181. Canada Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 182. Canada Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 183. Canada Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 184. Canada Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 185. Canada Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 186. Mexico Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 187. Mexico Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. Mexico Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 189. Mexico Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 190. Mexico Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 191. Mexico Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 192. Mexico Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 193. Mexico Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 194. Brazil Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 195. Brazil Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 196. Brazil Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 197. Brazil Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 198. Brazil Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 199. Brazil Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 200. Brazil Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 201. Brazil Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 202. United Kingdom Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 203. United Kingdom Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 204. United Kingdom Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 205. United Kingdom Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 206. United Kingdom Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 207. United Kingdom Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 208. United Kingdom Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 209. United Kingdom Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 210. Germany Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 211. Germany Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 212. Germany Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 213. Germany Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 214. Germany Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 215. Germany Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 216. Germany Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 217. Germany Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 218. France Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 219. France Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 220. France Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 221. France Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 222. France Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 223. France Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 224. France Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 225. France Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 226. Russia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 227. Russia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 228. Russia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 229. Russia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 230. Russia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 231. Russia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 232. Russia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 233. Russia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 234. Italy Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 235. Italy Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 236. Italy Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 237. Italy Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 238. Italy Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 239. Italy Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 240. Italy Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 241. Italy Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 242. Spain Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 243. Spain Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 244. Spain Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 245. Spain Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 246. Spain Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 247. Spain Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 248. Spain Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 249. Spain Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 250. China Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 251. China Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 252. China Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 253. China Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 254. China Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 255. China Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 256. China Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 257. China Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 258. India Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 259. India Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 260. India Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 261. India Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 262. India Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 263. India Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 264. India Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 265. India Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 266. Japan Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 267. Japan Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 268. Japan Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 269. Japan Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 270. Japan Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 271. Japan Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 272. Japan Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 273. Japan Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 274. Australia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 275. Australia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 276. Australia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 277. Australia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 278. Australia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 279. Australia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 280. Australia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 281. Australia Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 282. South Korea Anti-a4ß7 Integrin Monoclonal Antibody Market Size, 2017-2032 (USD Million)
TABLE 283. South Korea Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Indication, 2017-2032 (USD Million)
TABLE 284. South Korea Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Crohn's Disease, 2017-2032 (USD Million)
TABLE 285. South Korea Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 286. South Korea Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 287. South Korea Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 288. South Korea Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 289. South Korea Anti-a4ß7 Integrin Monoclonal Antibody Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 290. Global Anti-a4ß7 Integrin Monoclonal Antibody Market Share, by Key Player, 2025
TABLE 291. Global Anti-a4ß7 Integrin Monoclonal Antibody Market, Key Experts

Companies Mentioned

  • Abcam
  • ACROBiosystems
  • Aladdin Scientific
  • Biorbyt
  • Bioss Inc.
  • BosterBio
  • Creative Diagnostics
  • GeneTex
  • ichorbio
  • Leinco Technologies
  • MyBioSource.com
  • Novus Biologicals
  • OriGene Technologies
  • R&D Systems
  • Santa Cruz Biotechnology, Inc.
  • Selleck Chemicals
  • Sino Biological
  • Thermo Fisher Scientific
  • United States Biological

Related Topics

Related Reports

Anti-amyloid-ß Monoclonal Antibodies Market - Global Forecast 2026-2032 - Product Image

Anti-amyloid-ß Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
RGD Peptide Market - Global Forecast 2026-2032 - Product Image

RGD Peptide Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Antibody Therapeutics Market - Global Strategic Business Report - Product Image

Antibody Therapeutics Market - Global Strategic Business Report

  • Report
  • 577 Pages
  • Global
From
Monoclonal Antibodies - Competitive Landscape, 2026 - Product Image

Monoclonal Antibodies - Competitive Landscape, 2026

  • Report
  • 450 Pages
  • Global
From
Thymic Carcinoma Pipeline Analysis Report 2026 - Product Image

Thymic Carcinoma Pipeline Analysis Report 2026

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.